Pulse Biosciences, the Hayward, California-based bioelectric medicine developer (Nasdaq: PLSE), reported updated 12-month results from the first-in-human feasibility study of its nPulse Cardiac Catheter System at the Heart Rhythm 2026 meeting on April 25. The expanded dataset, drawn from 177 patients treated across seven European investigator sites, showed 96% procedural success by holter monitoring at one year and a 90% Kaplan-Meier estimate of freedom from atrial fibrillation, atrial flutter, and atrial tachycardia, positioning the company’s nanosecond pulsed field ablation platform as a credible long-duration challenger in a market now dominated by Boston Scientific, Medtronic, and Johnson & Johnson.
What the expanded follow-up actually changes for nsPFA’s clinical case
The headline shift in this readout is not the percentages, which are broadly consistent with what Pulse Biosciences disclosed at the AF Symposium in February. It is the n. The six-month evaluable cohort grew to 95 patients from 75, and the 12-month cohort grew to 53 from 47. Sustaining a 100% holter-confirmed success rate as the six-month population scales is meaningful in early-stage feasibility work, where attrition and added variability typically erode initial signals. The 90% Kaplan-Meier estimate of freedom from AF, atrial flutter, and atrial tachycardia at 12 months is the more clinically demanding metric and the one regulators and payers will weigh when the system eventually approaches an investigational device exemption pathway in the United States.
The benchmark to beat is no longer theoretical. Kardium’s pivotal trial, also presented by Vivek Reddy at the Heart Rhythm Society earlier this cycle, posted a 78% one-year freedom from atrial arrhythmia rate in paroxysmal AF patients with 95% durable vein isolation. Boston Scientific’s Farapulse, the dominant commercial system, has reported 12-month freedom-from-arrhythmia rates in the high 70s to low 80s across registry settings. A 90% number from Pulse Biosciences, even at feasibility stage, sits at the upper end of what the field has demonstrated, but the asterisks matter. This is a single-arm, non-randomized study weighted toward experienced operators at high-volume centers including Na Homolce Hospital in Prague, Jessa Hospital in Hasselt, and Tor Vergata Hospital in Rome, with principal investigators who have repeatedly delivered favorable PFA results across multiple platforms. Performance under broader real-world conditions remains unproven, and the company has yet to disclose results from a randomized comparative trial.
Why the procedural efficiency numbers carry strategic weight
Left atrial dwell time of 18.6 minutes, total procedure time of 60.2 minutes, and an average of 12.3 applications per patient for pulmonary vein isolation are the operationally important figures in this readout, possibly more so than the efficacy percentages. Hospital electrophysiology labs are buying PFA on throughput economics as much as clinical performance, and the rapid commercial trajectory of Boston Scientific’s Farapulse demonstrated that the procedural workflow advantage drives adoption faster than incremental efficacy improvements. A sub-20-minute left atrial dwell time and a one-hour total procedure window puts the nPulse catheter in roughly the same operational tier as Farapulse and Medtronic’s Affera, which is the threshold the system needs to cross to be commercially viable when it eventually reaches market.
Where nsPFA differentiates, at least in the company’s framing, is the underlying energy mechanism. Conventional pulsed field ablation systems use microsecond pulses. Pulse Biosciences uses pulses lasting billionths of a second, which preclinical data suggests can generate deeper cardiac lesions at matched energy. Whether that translates into a clinically meaningful durability advantage over the established microsecond platforms is the central scientific question facing the company, and a 12-month freedom-from-arrhythmia readout in a non-randomized cohort cannot answer it. A head-to-head trial against Farapulse or Affera would. Until then, the differentiation case rests largely on internal preclinical comparisons and benchmarked efficacy figures from non-comparable populations.
What this reveals about Pulse Biosciences’ positioning in a tightening field
The competitive context for any small PFA developer in 2026 is unforgiving. Boston Scientific’s Farapulse held more than 70% global market share at last disclosure, with electrophysiology revenue more than doubling year over year. Medtronic’s Affera Sphere-9, which delivers both PFA and radiofrequency energy from a lattice tip catheter, is expected to cannibalize the company’s earlier PulseSelect offering and capture significant share. Johnson & Johnson’s Varipulse, integrated with the Carto mapping system, secured U.S. approval in late 2024. Abbott’s Volt entered the market in early 2026. Kardium received Food and Drug Administration authorization for its Globe system in 2025 and raised $250 million for commercialization. Industry analysts have repeatedly named Pulse Biosciences among smaller PFA developers that larger medtech players may consider acquiring to gain technology depth or market position, alongside Field Medical, Adagio Medical, Acutus Medical, and Cardiofocus.
This dynamic shapes how the Heart Rhythm 2026 data should be read. Pulse Biosciences is not realistically going to launch a commercial cardiac ablation system into the United States independently against four well-capitalized incumbents. The clinical readout therefore functions as much as a strategic asset as a regulatory milestone. Sustained durability and competitive procedure times across a multi-site European cohort strengthen the company’s case in any acquisition or licensing conversation, and they support a U.S. investigational device exemption application that would extend the data into a randomized setting. Whether either path materializes on a useful timeline is the question the market is now pricing.
What clinicians, regulators, and investors will watch from here
Three unresolved questions overhang the readout. The first is whether the 12-month durability holds as the cohort matures further and as the company moves into less selected operator and patient populations. Kaplan-Meier estimates at one year are useful but historically have softened at two and three years across PFA platforms, and the more rigorous test is sustained performance through the 24-month and 36-month windows that influence guideline positioning and payer behavior. The second is the safety profile beyond the primary endpoint. The reported 1.7% serious adverse event rate across the 177-patient cohort is consistent with current PFA expectations, but esophageal, phrenic nerve, and pulmonary vein stenosis signals tend to surface in larger and more heterogeneous populations than feasibility studies capture. The third is the regulatory path itself. The company has signalled intent to advance the cardiac catheter through to a paroxysmal AF indication, but no timeline for an investigational device exemption submission, pivotal trial design, or U.S. patient enrollment has been publicly committed.
For the broader pulsed field ablation field, the readout is one more data point reinforcing that PFA in general is delivering durable pulmonary vein isolation across multiple energy modalities and catheter designs. The nanosecond approach now joins microsecond PFA, lattice-tip integrated platforms, and globe-array systems as another credible variant. What remains genuinely contested is whether any of these technical differentiators will translate into clinical or commercial separation in a market where the leading platform already has scale, mapping integration, payer familiarity, and physician training infrastructure on its side. Pulse Biosciences has produced a clean dataset. The harder test is whether a clean dataset is enough to disrupt a market that has effectively consolidated around three names in under three years.
Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →